Loading...
Adjuvant chemotherapy is standard for patients who have stage III colon cancer, but it provides limited benefit for patients who have stage II disease without high-risk features. To assess the risk for recurrence and the degree of benefit from adjuvant chemotherapy in patients with standard-risk (node-negative) stage II colon cancer, investigators report the large-scale validation of a recurrence score and a treatment score based on a quantitative multigene reverse-transcriptase–polymerase chain reaction (RT-PCR) assessment of tumor tissue. The researchers examined 1399 tissue samples from 1436 eligible patients (42% female) who were treated with adjuvant 5-fluorouracil (5-FU) chemotherapy versus observation after curative resection in the …